Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347425 · ClinicalTrials.gov registry record · Phase 3
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT00347425 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 286 participants.
The verdict
NCT00347425, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Ziprasidone
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347425
The ClinicalTrials.gov registry entry for NCT00347425 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Risperidone is the first listed.
NCT00347425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00347425 about?
NCT00347425 is a clinical study titled "Switch Study of Existing Atypical Antipsychotics to Bifeprunox". The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
What is the current status of trial NCT00347425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2006-12. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00347425?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Ziprasidone (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00347425?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.